Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study
Aim Until now, no effective adjuvant therapy to prevent early recurrence of hepatocellular carcinoma (HCC) after curative treatment has been reported. The aim of this study is to evaluate the clinical benefit of sorafenib as adjuvant treatment in subjects with HCC after hepatic resection. Methods Th...
Saved in:
| Published in | Hepatology research Vol. 44; no. 5; pp. 523 - 531 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Blackwell Publishing Ltd
01.05.2014
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Aim
Until now, no effective adjuvant therapy to prevent early recurrence of hepatocellular carcinoma (HCC) after curative treatment has been reported. The aim of this study is to evaluate the clinical benefit of sorafenib as adjuvant treatment in subjects with HCC after hepatic resection.
Methods
The pilot study was undertaken involving HCC patients who had undergone curative liver surgery with high recurrence risk factors. Time to recurrence and disease recurrence rate were assessed. Sorafenib 400 mg q.d. was administrated continuously for 4 months after hepatic resection.
Results
A total of 31 patients were enrolled and eligible for final data analysis. The median follow‐up time was 19 months (range, 9.5–30.2). Time to recurrence in the sorafenib arm was 21.45 ± 1.98 months (mean ± standard deviation), compared to 13.44 ± 2.66 months in the control arm (P = 0.006). The median recurrence‐free survival in the sorafenib arm did not reach the data cut‐off date compared to 8 months in the control arm (P = 0.006). The recurrence rate between the two groups was significantly different (29.4% vs 70.7%, P = 0.032). Cox regression analysis showed that taking study medicine was the only prognostic variable associated with HCC recurrence (hazard ratio = 0.24, 95% confidence interval = 0.08–0.75, P = 0.014).
Conclusion
This study showed that setting sorafenib as adjuvant therapy for HCC to prevent early recurrence after hepatic resection could be a potential indication. The cumulative recurrence‐free survival rate also demonstrated the preventive effectiveness of sorafenib. |
|---|---|
| AbstractList | Aim
Until now, no effective adjuvant therapy to prevent early recurrence of hepatocellular carcinoma (HCC) after curative treatment has been reported. The aim of this study is to evaluate the clinical benefit of sorafenib as adjuvant treatment in subjects with HCC after hepatic resection.
Methods
The pilot study was undertaken involving HCC patients who had undergone curative liver surgery with high recurrence risk factors. Time to recurrence and disease recurrence rate were assessed. Sorafenib 400 mg q.d. was administrated continuously for 4 months after hepatic resection.
Results
A total of 31 patients were enrolled and eligible for final data analysis. The median follow‐up time was 19 months (range, 9.5–30.2). Time to recurrence in the sorafenib arm was 21.45 ± 1.98 months (mean ± standard deviation), compared to 13.44 ± 2.66 months in the control arm (P = 0.006). The median recurrence‐free survival in the sorafenib arm did not reach the data cut‐off date compared to 8 months in the control arm (P = 0.006). The recurrence rate between the two groups was significantly different (29.4% vs 70.7%, P = 0.032). Cox regression analysis showed that taking study medicine was the only prognostic variable associated with HCC recurrence (hazard ratio = 0.24, 95% confidence interval = 0.08–0.75, P = 0.014).
Conclusion
This study showed that setting sorafenib as adjuvant therapy for HCC to prevent early recurrence after hepatic resection could be a potential indication. The cumulative recurrence‐free survival rate also demonstrated the preventive effectiveness of sorafenib. Until now, no effective adjuvant therapy to prevent early recurrence of hepatocellular carcinoma (HCC) after curative treatment has been reported. The aim of this study is to evaluate the clinical benefit of sorafenib as adjuvant treatment in subjects with HCC after hepatic resection. The pilot study was undertaken involving HCC patients who had undergone curative liver surgery with high recurrence risk factors. Time to recurrence and disease recurrence rate were assessed. Sorafenib 400 mg q.d. was administrated continuously for 4 months after hepatic resection. A total of 31 patients were enrolled and eligible for final data analysis. The median follow-up time was 19 months (range, 9.5-30.2). Time to recurrence in the sorafenib arm was 21.45 ± 1.98 months (mean ± standard deviation), compared to 13.44 ± 2.66 months in the control arm (P = 0.006). The median recurrence-free survival in the sorafenib arm did not reach the data cut-off date compared to 8 months in the control arm (P = 0.006). The recurrence rate between the two groups was significantly different (29.4% vs 70.7%, P = 0.032). Cox regression analysis showed that taking study medicine was the only prognostic variable associated with HCC recurrence (hazard ratio = 0.24, 95% confidence interval = 0.08-0.75, P = 0.014). This study showed that setting sorafenib as adjuvant therapy for HCC to prevent early recurrence after hepatic resection could be a potential indication. The cumulative recurrence-free survival rate also demonstrated the preventive effectiveness of sorafenib. Until now, no effective adjuvant therapy to prevent early recurrence of hepatocellular carcinoma (HCC) after curative treatment has been reported. The aim of this study is to evaluate the clinical benefit of sorafenib as adjuvant treatment in subjects with HCC after hepatic resection.AIMUntil now, no effective adjuvant therapy to prevent early recurrence of hepatocellular carcinoma (HCC) after curative treatment has been reported. The aim of this study is to evaluate the clinical benefit of sorafenib as adjuvant treatment in subjects with HCC after hepatic resection.The pilot study was undertaken involving HCC patients who had undergone curative liver surgery with high recurrence risk factors. Time to recurrence and disease recurrence rate were assessed. Sorafenib 400 mg q.d. was administrated continuously for 4 months after hepatic resection.METHODSThe pilot study was undertaken involving HCC patients who had undergone curative liver surgery with high recurrence risk factors. Time to recurrence and disease recurrence rate were assessed. Sorafenib 400 mg q.d. was administrated continuously for 4 months after hepatic resection.A total of 31 patients were enrolled and eligible for final data analysis. The median follow-up time was 19 months (range, 9.5-30.2). Time to recurrence in the sorafenib arm was 21.45 ± 1.98 months (mean ± standard deviation), compared to 13.44 ± 2.66 months in the control arm (P = 0.006). The median recurrence-free survival in the sorafenib arm did not reach the data cut-off date compared to 8 months in the control arm (P = 0.006). The recurrence rate between the two groups was significantly different (29.4% vs 70.7%, P = 0.032). Cox regression analysis showed that taking study medicine was the only prognostic variable associated with HCC recurrence (hazard ratio = 0.24, 95% confidence interval = 0.08-0.75, P = 0.014).RESULTSA total of 31 patients were enrolled and eligible for final data analysis. The median follow-up time was 19 months (range, 9.5-30.2). Time to recurrence in the sorafenib arm was 21.45 ± 1.98 months (mean ± standard deviation), compared to 13.44 ± 2.66 months in the control arm (P = 0.006). The median recurrence-free survival in the sorafenib arm did not reach the data cut-off date compared to 8 months in the control arm (P = 0.006). The recurrence rate between the two groups was significantly different (29.4% vs 70.7%, P = 0.032). Cox regression analysis showed that taking study medicine was the only prognostic variable associated with HCC recurrence (hazard ratio = 0.24, 95% confidence interval = 0.08-0.75, P = 0.014).This study showed that setting sorafenib as adjuvant therapy for HCC to prevent early recurrence after hepatic resection could be a potential indication. The cumulative recurrence-free survival rate also demonstrated the preventive effectiveness of sorafenib.CONCLUSIONThis study showed that setting sorafenib as adjuvant therapy for HCC to prevent early recurrence after hepatic resection could be a potential indication. The cumulative recurrence-free survival rate also demonstrated the preventive effectiveness of sorafenib. |
| Author | Lee, King-Teh Wang, Shen-Nien Chuang, Shih-Cheng |
| Author_xml | – sequence: 1 givenname: Shen-Nien surname: Wang fullname: Wang, Shen-Nien organization: Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University – sequence: 2 givenname: Shih-Cheng surname: Chuang fullname: Chuang, Shih-Cheng organization: Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University – sequence: 3 givenname: King-Teh surname: Lee fullname: Lee, King-Teh email: ktlee@kmu.edu.tw organization: Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23672310$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kctu1DAUhi1URC-w4QGQlwgpxY4TO8OuGg0tUgUIFcrOOnGOqUsmTm1nIE_Q166HabtACC980_cd_TrnkOwNfkBCXnJ2zPN6e4VjOOYlrxdPyAFvVFkwUX3fy3fRyEKKSu6TwxivGeOKldUzsl8KqUrB2QG5XVnrDJiZekujD2BxcC2FSKG7njYwJJquMMA40-TpGHCD-Qsh9DMNaKYQcDC4lXMKSN5g3089BGogGDf4NVCwCfN7CpDcBmmcwg8M8zt6QkfX-0Rjmrr5OXlqoY_44v48Il_fry6WZ8X5p9MPy5PzwlS1WhQKrYUGTCeQg20Yz9EX3DQVq2VTSWa7ClushWwZk2VrbWUU78rMg2Amb0fk9a7uGPzNhDHptYvb0DCgn6LmNVdNI0rFMvrqHp3aNXZ6DG4NYdYPzcvAmx1ggo8xoH1EONPbyejtZPSfyWSY_QUbl3JH_JACuP7fCt8pv1yP83-K67PV5y8PTrFzXEz4-9GB8FNLJVStLz-eav5NLEt1KfWFuAMjfLMT |
| CitedBy_id | crossref_primary_10_4251_wjgo_v14_i9_1604 crossref_primary_10_1007_s00432_023_04874_0 crossref_primary_10_1159_000509424 crossref_primary_10_1186_s13045_019_0794_6 crossref_primary_10_4240_wjgs_v15_i1_19 crossref_primary_10_1038_ajg_2015_83 crossref_primary_10_1016_S1665_2681_19_30919_6 crossref_primary_10_1158_1078_0432_CCR_17_2899 crossref_primary_10_1186_s12957_021_02280_9 crossref_primary_10_1016_j_media_2022_102575 crossref_primary_10_1016_j_cld_2015_01_009 crossref_primary_10_3390_cancers16071422 crossref_primary_10_2217_fon_15_85 crossref_primary_10_1016_j_clinre_2023_102165 crossref_primary_10_1007_s13277_015_4279_0 crossref_primary_10_1038_s41392_020_00264_x crossref_primary_10_3748_wjg_v22_i23_5384 crossref_primary_10_3389_fonc_2022_1101351 crossref_primary_10_1007_s40820_021_00647_x crossref_primary_10_18632_oncotarget_3799 crossref_primary_10_1007_s10353_019_0573_1 crossref_primary_10_3389_fonc_2021_633033 crossref_primary_10_3892_ol_2014_2727 crossref_primary_10_1177_0300060520946872 crossref_primary_10_4254_wjh_v15_i2_129 crossref_primary_10_1007_s11864_014_0291_7 crossref_primary_10_3390_cancers15112950 crossref_primary_10_1002_cam4_6277 crossref_primary_10_1111_jgh_13843 crossref_primary_10_1177_1756284820977693 crossref_primary_10_1186_s12876_016_0427_2 crossref_primary_10_1007_s13277_014_2443_6 crossref_primary_10_3389_fonc_2020_605057 crossref_primary_10_1155_2020_4037639 crossref_primary_10_3390_biomedicines9101345 crossref_primary_10_3892_mco_2015_677 crossref_primary_10_3390_diseases4010001 crossref_primary_10_1002_ijc_29203 crossref_primary_10_1007_s00261_018_1646_5 crossref_primary_10_3892_ol_2016_5525 crossref_primary_10_5582_bst_2014_01120 crossref_primary_10_1002_cam4_7018 crossref_primary_10_1245_s10434_021_10142_7 crossref_primary_10_11569_wcjd_v27_i23_1407 crossref_primary_10_1016_j_gendis_2020_03_010 crossref_primary_10_3389_fimmu_2023_1202039 crossref_primary_10_3748_wjg_v23_i41_7415 crossref_primary_10_1007_s11684_021_0848_3 crossref_primary_10_1159_000368017 crossref_primary_10_18632_oncotarget_21299 crossref_primary_10_1002_jhbp_114 crossref_primary_10_3390_curroncol30120737 crossref_primary_10_1159_000521596 crossref_primary_10_1002_jso_25305 crossref_primary_10_1177_1010428317695030 crossref_primary_10_3389_fonc_2023_1138570 crossref_primary_10_4137_CGast_S30190 crossref_primary_10_2147_JHC_S424616 crossref_primary_10_1177_17588359241258394 crossref_primary_10_3390_curroncol30030243 |
| Cites_doi | 10.1002/bjs.8915 10.1016/S0168-8278(02)00360-4 10.1517/13543784.2011.588598 10.1097/00000658-199108000-00004 10.1001/archsurg.133.2.183 10.1097/01.sla.0000197706.21803.a1 10.1245/s10434-008-0232-4 10.1002/lt.20039 10.1002/bjs.7393 10.1200/JCO.2002.20.6.1527 10.1016/j.jhep.2009.12.041 10.1016/S1590-8658(10)60513-0 10.1002/bjs.7583 10.1016/j.jfma.2011.02.002 10.1097/00000658-200203000-00009 10.1002/hep.24075 10.1056/NEJMra1001683 10.1111/j.1872-034X.2012.00981.x 10.1016/S1470-2045(08)70285-7 10.1002/path.1287 10.1002/1097-0142(20010415)91:8<1479::AID-CNCR1155>3.0.CO;2-0 10.1002/hep.510250116 10.1111/j.1365-2036.2011.04634.x 10.1097/SLA.0b013e31821ad884 10.1016/j.jhep.2008.01.022 10.1016/j.jhep.2009.07.009 10.1002/hep.20933 10.1159/000333259 10.1097/00000658-200007000-00003 10.1053/j.gastro.2007.04.061 10.1053/gast.2000.9373 10.1002/bjs.1800820141 10.1097/01.SLA.0000059988.22416.F2 10.1002/ijc.25516 10.1002/jso.21248 10.1056/NEJMoa0708857 10.1111/j.1365-2893.2009.01181.x 10.1002/hep.24199 10.1055/s-2005-871198 10.1002/jso.21786 10.1053/jhep.2003.50134 10.1111/j.1365-2036.2006.02932.x |
| ContentType | Journal Article |
| Copyright | 2013 The Japan Society of Hepatology 2013 The Japan Society of Hepatology. |
| Copyright_xml | – notice: 2013 The Japan Society of Hepatology – notice: 2013 The Japan Society of Hepatology. |
| DBID | BSCLL AAYXX CITATION NPM 7X8 |
| DOI | 10.1111/hepr.12159 |
| DatabaseName | Istex CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1872-034X |
| EndPage | 531 |
| ExternalDocumentID | 23672310 10_1111_hepr_12159 HEPR12159 ark_67375_WNG_1V3C27W6_T |
| Genre | article Journal Article |
| GroupedDBID | --- --K .3N .GA .Y3 05W 0R~ 10A 1B1 1OC 1~5 29I 31~ 33P 3SF 4.4 4G. 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANLZ AAONW AAQFI AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABDBF ABEML ABIJN ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIUM ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADMUD ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AIACR AIAGR AITUG AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD ESX EX3 F00 F01 F04 F5P FDB FEDTE FGOYB FUBAC G-Q G-S G.N GODZA H.X HF~ HGLYW HVGLF HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NQ- O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K R2- RIG ROL RPZ RX1 SEW SSZ SUPJJ TEORI TUS UB1 UHS V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 ZZTAW ~IA ~WT AAHQN AAIPD AAMMB AAMNL AANHP AAYCA ABWVN ACRPL ACUHS ACVFH ACYXJ ADCNI ADNMO AEFGJ AEUPX AEYWJ AFPUW AFWVQ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIGII ALVPJ AAYXX CITATION NPM 7X8 |
| ID | FETCH-LOGICAL-c4579-7effa8acd3e1af801cac91c840568460fd4ebe536b0062bff4c71d2cd3a30c3a3 |
| IEDL.DBID | DR2 |
| ISSN | 1386-6346 |
| IngestDate | Fri Jul 11 09:47:57 EDT 2025 Thu Apr 03 07:06:22 EDT 2025 Tue Jul 01 01:58:12 EDT 2025 Thu Apr 24 23:02:56 EDT 2025 Wed Jul 16 12:24:48 EDT 2025 Wed Oct 30 09:55:40 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | liver resection adjuvant therapy sorafenib hepatocellular carcinoma |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2013 The Japan Society of Hepatology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4579-7effa8acd3e1af801cac91c840568460fd4ebe536b0062bff4c71d2cd3a30c3a3 |
| Notes | ArticleID:HEPR12159 ark:/67375/WNG-1V3C27W6-T istex:FDD638DA3BB92DE94D128039D28A8A96BFA66EE0 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 23672310 |
| PQID | 1517883270 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1517883270 pubmed_primary_23672310 crossref_primary_10_1111_hepr_12159 crossref_citationtrail_10_1111_hepr_12159 wiley_primary_10_1111_hepr_12159_HEPR12159 istex_primary_ark_67375_WNG_1V3C27W6_T |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | May 2014 |
| PublicationDateYYYYMMDD | 2014-05-01 |
| PublicationDate_xml | – month: 05 year: 2014 text: May 2014 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Hepatology research |
| PublicationTitleAlternate | Hepatol Res |
| PublicationYear | 2014 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390. Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P'eng FK. Preoperative transcatheter arterial chemoembolization for respectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82: 122-126. Fan ST, Poon RT, Yeung C et al. Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. Br J Surg 2011; 98: 1292-1300. EI-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127. Imamura H, Matsuyama Y, Tanaka E et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207. Cucchetti A, Piscaglia F, Caturelli E, Benvegnu L, Vivarelli M. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009; 16: 413-422. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: S20-37. Ferlay J, Shin HR, Bray F, Forman D, Mather SC, Parkin DM. Estimates of world wide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917. Portolani N, Coniglio A, Ghidoni S, Giovanelli M. Early and late recurrence after liver resection for hepatocellular carcinoma- prognostic and therapeutic lmplications. Ann Surg 2006; 243: 229-235. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-1547. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. Prints C. Clinical trials of note. Sorafenib as adjuvant treatment for the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 2009; 115: 4646. Wu JC, Huang TH, Chau GY et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51: 890-897. Kaneko S, Furuse J, Kudo M et al. Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update. Hepatol Res 2012; 42: 523-542. Wang Z, Hu J, Qiu SJ et al. An investigation of the effect of sorafenib on tumor growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. Expert Opin Investig Drugs 2011; 20: 1039-1045. Eguchi S, Kanematsu T, Arii S et al.; Liver Cancer Study Group of Japan. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011; 98: 552-557. Finkelstein SD, Marsh W, Demetris AJ et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003; 37: 87-89. Andreana L, Burroughs AK. Treatment of early hepatocellular carcinoma: how to predict and prevent recurrence. Dig Liver Dis 2010; 42: S249-257. Vauthey J, Lauwers G, Esnaola N et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20: 1527-1536. Zhon XD, Tang ZY, Yang BH et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91: 1479-1486. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17: 287-292. Ercolani G, Grazi GL, Ravaioli M et al. Liver resection for hepatocellular carcinoma on cirrhosis. Ann Surg 2003; 237: 536-543. Feng YX, Wang T, Deng YX et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotropic mouse model. Hepatology 2011; 53: 483-493. Chen Y, Yeh SH, Chen JT et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000; 119: 431-440. Wong JS, Wong GL, Tsoi KK et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 33: 1104-1112. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576. Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg 2012; 99: 1622-1629. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991; 214: 114-117. Lim KC, Chow PK, Allen JC et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 2011; 254: 108-113. Kumada T, Nakano S, Takeda I et al. Patterns of recurrence after intial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92. Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma. Arch Surg 1998; 133: 183-188. Chun JM, Kwon HJ, Sohn J et al. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol 2011; 103: 148-151. Lee KT, Wang SN, Su RW et al. Is wider surgical margin justified for better clinical outcomes in patients with resectable hepatocellular carcinoma? J Formos Med Assoc 2012; 111: 160-170. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022. Ng I, Guan X, Poon R, Fan ST, Lee JM. Determination of nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 2003; 199: 345-353. Plessier A, Codes L, Consigny Y, Sommacale D. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004; 10: S86-90. Lee KT, Lu YW, Wang SN et al. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009; 99: 343-350. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma: a meta-regression approach. J Hepatol 2010; 52: 889-894. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function : implications for a strategy of salvage transplantation. Ann Surg 2002; 235: 373-382. Poon RT, Fan ST, Wong J. Risk factor, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34. Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 2011; 81 (Suppl 1): 50-55. 2001; 91 2003; 237 2010; 127 2010; 17 2011; 81 2002; 235 1997; 25 2000; 119 2011; 53 2005; 42 2003; 37 2011; 33 2011; 98 2006 2003; 38 2000; 232 1998; 133 2012; 99 1991; 214 2003; 199 2011; 254 2009; 115 2005; 25 2004; 10 2009; 99 2011; 103 2010; 42 1995; 82 2012; 111 2009; 51 2009; 10 2006; 23 2002; 20 2007; 132 2011; 20 2008; 48 2008; 359 2011; 365 2009; 16 2010; 52 2006; 243 2012; 42 e_1_2_5_27_1 e_1_2_5_28_1 e_1_2_5_25_1 e_1_2_5_26_1 e_1_2_5_23_1 e_1_2_5_24_1 e_1_2_5_45_1 e_1_2_5_21_1 e_1_2_5_44_1 e_1_2_5_22_1 e_1_2_5_43_1 Prints C (e_1_2_5_42_1) 2009; 115 e_1_2_5_29_1 e_1_2_5_20_1 e_1_2_5_41_1 e_1_2_5_40_1 e_1_2_5_15_1 e_1_2_5_38_1 e_1_2_5_14_1 e_1_2_5_39_1 e_1_2_5_17_1 e_1_2_5_36_1 e_1_2_5_9_1 e_1_2_5_16_1 e_1_2_5_37_1 e_1_2_5_8_1 e_1_2_5_11_1 e_1_2_5_34_1 e_1_2_5_7_1 e_1_2_5_10_1 e_1_2_5_35_1 e_1_2_5_6_1 e_1_2_5_13_1 e_1_2_5_32_1 e_1_2_5_5_1 e_1_2_5_12_1 e_1_2_5_33_1 e_1_2_5_4_1 e_1_2_5_3_1 e_1_2_5_2_1 e_1_2_5_19_1 e_1_2_5_18_1 e_1_2_5_30_1 e_1_2_5_31_1 |
| References_xml | – reference: Prints C. Clinical trials of note. Sorafenib as adjuvant treatment for the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 2009; 115: 4646. – reference: Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022. – reference: Chen Y, Yeh SH, Chen JT et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000; 119: 431-440. – reference: Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma: a meta-regression approach. J Hepatol 2010; 52: 889-894. – reference: Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma. Arch Surg 1998; 133: 183-188. – reference: El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576. – reference: Lee KT, Wang SN, Su RW et al. Is wider surgical margin justified for better clinical outcomes in patients with resectable hepatocellular carcinoma? J Formos Med Assoc 2012; 111: 160-170. – reference: Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34. – reference: Vauthey J, Lauwers G, Esnaola N et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20: 1527-1536. – reference: Lim KC, Chow PK, Allen JC et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 2011; 254: 108-113. – reference: Cucchetti A, Piscaglia F, Caturelli E, Benvegnu L, Vivarelli M. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009; 16: 413-422. – reference: Portolani N, Coniglio A, Ghidoni S, Giovanelli M. Early and late recurrence after liver resection for hepatocellular carcinoma- prognostic and therapeutic lmplications. Ann Surg 2006; 243: 229-235. – reference: Ercolani G, Grazi GL, Ravaioli M et al. Liver resection for hepatocellular carcinoma on cirrhosis. Ann Surg 2003; 237: 536-543. – reference: Andreana L, Burroughs AK. Treatment of early hepatocellular carcinoma: how to predict and prevent recurrence. Dig Liver Dis 2010; 42: S249-257. – reference: Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991; 214: 114-117. – reference: Ng I, Guan X, Poon R, Fan ST, Lee JM. Determination of nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 2003; 199: 345-353. – reference: Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-1547. – reference: Wong JS, Wong GL, Tsoi KK et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 33: 1104-1112. – reference: Plessier A, Codes L, Consigny Y, Sommacale D. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004; 10: S86-90. – reference: Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390. – reference: Kumada T, Nakano S, Takeda I et al. Patterns of recurrence after intial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92. – reference: Zhon XD, Tang ZY, Yang BH et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91: 1479-1486. – reference: Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P'eng FK. Preoperative transcatheter arterial chemoembolization for respectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82: 122-126. – reference: Kaneko S, Furuse J, Kudo M et al. Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update. Hepatol Res 2012; 42: 523-542. – reference: Poon RT, Fan ST, Wong J. Risk factor, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24. – reference: Eguchi S, Kanematsu T, Arii S et al.; Liver Cancer Study Group of Japan. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011; 98: 552-557. – reference: Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: S20-37. – reference: Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function : implications for a strategy of salvage transplantation. Ann Surg 2002; 235: 373-382. – reference: Lee KT, Lu YW, Wang SN et al. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009; 99: 343-350. – reference: Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200. – reference: Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 2011; 81 (Suppl 1): 50-55. – reference: Imamura H, Matsuyama Y, Tanaka E et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207. – reference: Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg 2012; 99: 1622-1629. – reference: Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17: 287-292. – reference: Finkelstein SD, Marsh W, Demetris AJ et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003; 37: 87-89. – reference: Wang Z, Hu J, Qiu SJ et al. An investigation of the effect of sorafenib on tumor growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. Expert Opin Investig Drugs 2011; 20: 1039-1045. – reference: Fan ST, Poon RT, Yeung C et al. Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. Br J Surg 2011; 98: 1292-1300. – reference: Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. – reference: Chun JM, Kwon HJ, Sohn J et al. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol 2011; 103: 148-151. – reference: Wu JC, Huang TH, Chau GY et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51: 890-897. – reference: Feng YX, Wang T, Deng YX et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotropic mouse model. Hepatology 2011; 53: 483-493. – reference: Ferlay J, Shin HR, Bray F, Forman D, Mather SC, Parkin DM. Estimates of world wide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917. – reference: EI-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127. – volume: 42 start-page: S249 year: 2010 end-page: 257 article-title: Treatment of early hepatocellular carcinoma: how to predict and prevent recurrence publication-title: Dig Liver Dis – volume: 37 start-page: 87 year: 2003 end-page: 89 article-title: Microdissection‐based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma publication-title: Hepatology – volume: 16 start-page: 413 year: 2009 end-page: 422 article-title: Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population publication-title: Ann Surg Oncol – volume: 133 start-page: 183 year: 1998 end-page: 188 article-title: Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma publication-title: Arch Surg – volume: 115 start-page: 4646 year: 2009 article-title: Clinical trials of note. Sorafenib as adjuvant treatment for the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM) publication-title: Cancer – volume: 10 start-page: 25 year: 2009 end-page: 34 article-title: Efficacy and safety of sorafenib in patients in the Asia‐Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double‐blind, placebo‐controlled trial publication-title: Lancet Oncol – volume: 82 start-page: 122 year: 1995 end-page: 126 article-title: Preoperative transcatheter arterial chemoembolization for respectable large hepatocellular carcinoma: a reappraisal publication-title: Br J Surg – volume: 132 start-page: 2557 year: 2007 end-page: 2576 article-title: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis publication-title: Gastroenterology – volume: 10 start-page: S86 year: 2004 end-page: 90 article-title: Underestimation of the influence of satellite nodules as a risk factor for post‐transplantation recurrence in patients with small hepatocellular carcinoma publication-title: Liver Transpl – volume: 25 start-page: 181 year: 2005 end-page: 200 article-title: Resection and liver transplantation for hepatocellular carcinoma publication-title: Semin Liver Dis – volume: 91 start-page: 1479 year: 2001 end-page: 1486 article-title: Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma publication-title: Cancer – volume: 365 start-page: 1118 year: 2011 end-page: 1127 article-title: Hepatocellular carcinoma publication-title: N Engl J Med – volume: 235 start-page: 373 year: 2002 end-page: 382 article-title: Long‐term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function : implications for a strategy of salvage transplantation publication-title: Ann Surg – volume: 38 start-page: 200 year: 2003 end-page: 207 article-title: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy publication-title: J Hepatol – volume: 25 start-page: 87 year: 1997 end-page: 92 article-title: Patterns of recurrence after intial treatment in patients with small hepatocellular carcinoma publication-title: Hepatology – volume: 53 start-page: 1020 year: 2011 end-page: 1022 article-title: Management of hepatocellular carcinoma: an update publication-title: Hepatology – volume: 81 start-page: 50 issue: Suppl 1 year: 2011 end-page: 55 article-title: Adjuvant therapy after curative treatment for hepatocellular carcinoma publication-title: Oncology – volume: 52 start-page: 889 year: 2010 end-page: 894 article-title: Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma: a meta‐regression approach publication-title: J Hepatol – volume: 48 start-page: S20 year: 2008 end-page: 37 article-title: Novel advancements in the management of hepatocellular carcinoma in 2008 publication-title: J Hepatol – volume: 99 start-page: 1622 year: 2012 end-page: 1629 article-title: Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria publication-title: Br J Surg – volume: 99 start-page: 343 year: 2009 end-page: 350 article-title: The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes publication-title: J Surg Oncol – volume: 359 start-page: 378 year: 2008 end-page: 390 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med – volume: 17 start-page: 287 year: 2010 end-page: 292 article-title: Meta‐analysis: interferon‐alpha prevents the recurrence after curative treatment of hepatitis C virus‐related hepatocellular carcinoma publication-title: J Viral Hepat – volume: 103 start-page: 148 year: 2011 end-page: 151 article-title: Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma publication-title: J Surg Oncol – volume: 98 start-page: 552 year: 2011 end-page: 557 article-title: Recurrence‐free survival more than 10 years after liver resection for hepatocellular carcinoma publication-title: Br J Surg – volume: 98 start-page: 1292 year: 2011 end-page: 1300 article-title: Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria publication-title: Br J Surg – volume: 23 start-page: 1535 year: 2006 end-page: 1547 article-title: Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials publication-title: Aliment Pharmacol Ther – volume: 42 start-page: 1208 year: 2005 end-page: 1236 article-title: Management of hepatocellular carcinoma publication-title: Hepatology – volume: 214 start-page: 114 year: 1991 end-page: 117 article-title: Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis publication-title: Ann Surg – volume: 51 start-page: 890 year: 2009 end-page: 897 article-title: Risk factors for early and late recurrence in hepatitis B‐related hepatocellular carcinoma publication-title: J Hepatol – volume: 20 start-page: 1039 year: 2011 end-page: 1045 article-title: An investigation of the effect of sorafenib on tumor growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal‐regulated kinase levels publication-title: Expert Opin Investig Drugs – volume: 33 start-page: 1104 year: 2011 end-page: 1112 article-title: Meta‐analysis: the efficacy of anti‐viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B‐related hepatocellular carcinoma publication-title: Aliment Pharmacol Ther – volume: 20 start-page: 1527 year: 2002 end-page: 1536 article-title: Simplified staging for hepatocellular carcinoma publication-title: J Clin Oncol – volume: 232 start-page: 10 year: 2000 end-page: 24 article-title: Risk factor, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma publication-title: Ann Surg – year: 2006 – volume: 199 start-page: 345 year: 2003 end-page: 353 article-title: Determination of nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis publication-title: J Pathol – volume: 53 start-page: 483 year: 2011 end-page: 493 article-title: Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotropic mouse model publication-title: Hepatology – volume: 119 start-page: 431 year: 2000 end-page: 440 article-title: Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma publication-title: Gastroenterology – volume: 243 start-page: 229 year: 2006 end-page: 235 article-title: Early and late recurrence after liver resection for hepatocellular carcinoma‐ prognostic and therapeutic lmplications publication-title: Ann Surg – volume: 254 start-page: 108 year: 2011 end-page: 113 article-title: Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria publication-title: Ann Surg – volume: 111 start-page: 160 year: 2012 end-page: 170 article-title: Is wider surgical margin justified for better clinical outcomes in patients with resectable hepatocellular carcinoma? publication-title: J Formos Med Assoc – volume: 127 start-page: 2893 year: 2010 end-page: 2917 article-title: Estimates of world wide burden of cancer in 2008: GLOBOCAN 2008 publication-title: Int J Cancer – volume: 42 start-page: 523 year: 2012 end-page: 542 article-title: Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update publication-title: Hepatol Res – volume: 237 start-page: 536 year: 2003 end-page: 543 article-title: Liver resection for hepatocellular carcinoma on cirrhosis publication-title: Ann Surg – ident: e_1_2_5_22_1 doi: 10.1002/bjs.8915 – ident: e_1_2_5_23_1 doi: 10.1016/S0168-8278(02)00360-4 – ident: e_1_2_5_43_1 doi: 10.1517/13543784.2011.588598 – ident: e_1_2_5_33_1 doi: 10.1097/00000658-199108000-00004 – ident: e_1_2_5_40_1 doi: 10.1001/archsurg.133.2.183 – volume: 115 start-page: 4646 year: 2009 ident: e_1_2_5_42_1 article-title: Clinical trials of note. Sorafenib as adjuvant treatment for the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM) publication-title: Cancer – ident: e_1_2_5_24_1 doi: 10.1097/01.sla.0000197706.21803.a1 – ident: e_1_2_5_9_1 doi: 10.1245/s10434-008-0232-4 – ident: e_1_2_5_25_1 doi: 10.1002/lt.20039 – ident: e_1_2_5_13_1 doi: 10.1002/bjs.7393 – ident: e_1_2_5_31_1 doi: 10.1200/JCO.2002.20.6.1527 – ident: e_1_2_5_38_1 doi: 10.1016/j.jhep.2009.12.041 – ident: e_1_2_5_19_1 doi: 10.1016/S1590-8658(10)60513-0 – ident: e_1_2_5_12_1 doi: 10.1002/bjs.7583 – ident: e_1_2_5_14_1 doi: 10.1016/j.jfma.2011.02.002 – ident: e_1_2_5_32_1 doi: 10.1097/00000658-200203000-00009 – ident: e_1_2_5_44_1 doi: 10.1002/hep.24075 – ident: e_1_2_5_3_1 doi: 10.1056/NEJMra1001683 – ident: e_1_2_5_45_1 doi: 10.1111/j.1872-034X.2012.00981.x – ident: e_1_2_5_17_1 doi: 10.1016/S1470-2045(08)70285-7 – ident: e_1_2_5_29_1 doi: 10.1002/path.1287 – ident: e_1_2_5_30_1 doi: 10.1002/1097-0142(20010415)91:8<1479::AID-CNCR1155>3.0.CO;2-0 – ident: e_1_2_5_34_1 doi: 10.1002/hep.510250116 – ident: e_1_2_5_36_1 doi: 10.1111/j.1365-2036.2011.04634.x – ident: e_1_2_5_10_1 doi: 10.1097/SLA.0b013e31821ad884 – ident: e_1_2_5_20_1 doi: 10.1016/j.jhep.2008.01.022 – ident: e_1_2_5_26_1 doi: 10.1016/j.jhep.2009.07.009 – ident: e_1_2_5_15_1 doi: 10.1002/hep.20933 – ident: e_1_2_5_18_1 doi: 10.1159/000333259 – ident: e_1_2_5_41_1 doi: 10.1097/00000658-200007000-00003 – ident: e_1_2_5_4_1 doi: 10.1053/j.gastro.2007.04.061 – ident: e_1_2_5_27_1 doi: 10.1053/gast.2000.9373 – ident: e_1_2_5_39_1 doi: 10.1002/bjs.1800820141 – ident: e_1_2_5_35_1 doi: 10.1097/01.SLA.0000059988.22416.F2 – ident: e_1_2_5_2_1 doi: 10.1002/ijc.25516 – ident: e_1_2_5_21_1 – ident: e_1_2_5_11_1 doi: 10.1002/jso.21248 – ident: e_1_2_5_16_1 doi: 10.1056/NEJMoa0708857 – ident: e_1_2_5_37_1 doi: 10.1111/j.1365-2893.2009.01181.x – ident: e_1_2_5_5_1 doi: 10.1002/hep.24199 – ident: e_1_2_5_8_1 doi: 10.1055/s-2005-871198 – ident: e_1_2_5_7_1 doi: 10.1002/jso.21786 – ident: e_1_2_5_28_1 doi: 10.1053/jhep.2003.50134 – ident: e_1_2_5_6_1 doi: 10.1111/j.1365-2036.2006.02932.x |
| SSID | ssj0017024 |
| Score | 2.3284864 |
| Snippet | Aim
Until now, no effective adjuvant therapy to prevent early recurrence of hepatocellular carcinoma (HCC) after curative treatment has been reported. The aim... Until now, no effective adjuvant therapy to prevent early recurrence of hepatocellular carcinoma (HCC) after curative treatment has been reported. The aim of... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 523 |
| SubjectTerms | adjuvant therapy hepatocellular carcinoma liver resection sorafenib |
| Title | Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study |
| URI | https://api.istex.fr/ark:/67375/WNG-1V3C27W6-T/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhepr.12159 https://www.ncbi.nlm.nih.gov/pubmed/23672310 https://www.proquest.com/docview/1517883270 |
| Volume | 44 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9UwFA9jgvji90fnBxFFUOho2jRJxZcx7rwIGzI2txcJaZri3NZebnvB-Q_4b3tO0lYnQ9CX0oeTNk3PSX4nOed3CHlZsFwlyplY5cLFnKUsLtMqiwGaZgUAeikEJjjv7on5If9wnB-vkXdjLkzgh5g23NAy_HyNBm7K7jcj_-IWS8-NgNl7GKyFiGh_4o5iMhkq2ioRi4yLgZsUw3h-Nb20Gl3Dgf12FdS8jFz90rNzi3weOx0iTk43V325ab__wef4v191m9wcMCndCkp0h6y55i65vjucut8jP2bIM2HsBW1r2oHO1K45KanpqKm-rgCK9zSkcV3QvqWLQApFHVIn0yXu5_uMQmwM7wUnHw8LMPqVWixk1LTnhvpS5RREPQ857UKy9lu6RRcnZ21PPQvufXK4MzvYnsdDAYfY8lwWsXR1bZSxVeaYqWEthK4WzIJPmQvAPUldcdChPBNo-2lZ19xKVqUgb7LEwuUBWW_axj0i1OYuYZVCtrmCM-UKUxjlAMxZ8O9NxiPyevyR2g7s5lhk40yPXg6OrPYjG5EXk-wicHpcKfXK68MkYpanGAUnc320916zT9l2Ko-EPojI81FhNNgmjqFpXLvqNKApqWDKlElEHgZNmp6GzHmIrSPyxuvDX3qi57OP-_5u41-EH5MbgO54iM58Qtb75co9BQTVl8-8pfwEML4X3A |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaglYALb2h4GoGQqJQqThzH4VZVWxborlC1pb1ZjuOIPkhWm6xE-QP8bWbsbKCoQoJLlMM4cZwZ-xt75htCXuUslZG0OpSpsCFnMQuLuExCgKZJDoA-EwITnCdTMT7gH47Soz42B3NhPD_EsOGGluHmazRw3JD-zcq_2PnCkSPkV8k6lvR2HtX-wB7FsqivaStFKBIuenZSDOT51fbCerSOQ_vtMrB5Ebu6xWf3lq-w2jrOQow5Od1adsWW-f4Ho-N_f9dtcrOHpXTb69EdcsXWd8m1SX_wfo_8GCHVhDbntKloC2pT2fq4oLqlujxZAhrvqM_kOqddQ-eeF4paZE-mC9zSd0mF2BjeC34-nhdgACw1WMuobr5q6qqVUxB1VOS09fnab-k2nR-fNR11RLj3ycHuaLYzDvsaDqHhaZaHma0qLbUpE8t0BcshdDVnBtzKVAD0iaqSgxqliUDzj4uq4iZjZQzyOokMXB6Qtbqp7QahJrURKyUSzuWcSZvrXEsLeM6Ai68THpA3qz-pTE9wjnU2ztTK0cGRVW5kA_JykJ17Wo9LpV47hRhE9OIUA-GyVB1O3yn2OdmJs0OhZgF5sdIYBeaJY6hr2yxbBYAqkzBrZlFAHnpVGp6G5HkIrwOy6RTiLz1R49GnfXf36F-En5Pr49lkT-29n358TG4A2OM-WPMJWesWS_sUAFVXPHNm8xOQqxv3 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB6VVqp44T7CaQRCAilVDsdxEC9Vu8tydFVVLe0LshzHEaUliXazEuUP8LeZcZKFogoJXqI8jBPHmbG_sWe-AXiWhYkMpNW-TIT1eRiFfh4VsY_QNM4Q0KdCUILzzlRMDvi7o-RoBV4PuTAdP8Ryw40sw83XZOBNUf5m5J9tM3PcCNklWOMikKTT23tL8qgwDfqStlL4IuaiJyelOJ5fbc8tR2s0st8uwprnoatbe8ZX4dPQ6y7k5GRj0eYb5vsfhI7_-1nX4EoPStlmp0XXYcVWN2B9pz92vwk_RkQ0oc0Zq0s2R6UpbXWcMz1nuviyQCzesi6P64y1NWs6VihmiTuZzWhD36UUUmN8L3r5dFpA4a_MUCWjqv6qmatVzlDUEZGzeZet_Yptsub4tG6Zo8G9BQfj0f7WxO8rOPiGJ2nmp7YstdSmiG2oS1wMsatZaNCpTAQCn6AsOCpREgsy_igvS27SsIhQXseBwcttWK3qyt4FZhIbhIUkurmMh9JmOtPSIpoz6ODrmHvwYviRyvT05lRl41QNbg6NrHIj68HTpWzTkXpcKPXc6cNSRM9OKAwuTdTh9I0KP8ZbUXoo1L4HTwaFUWicNIa6svVirhBOpRLnzDTw4E6nScunEXUegWsPXjp9-EtP1GS0u-fu7v2L8GNY390eqw9vp-_vw2VEeryL1HwAq-1sYR8immrzR85ofgJOEhqv |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+sorafenib+as+adjuvant+therapy+to+prevent+early+recurrence+of+hepatocellular+carcinoma+after+curative+surgery%3A+A+pilot+study&rft.jtitle=Hepatology+research&rft.au=Wang%2C+Shen%E2%80%90Nien&rft.au=Chuang%2C+Shih%E2%80%90Cheng&rft.au=Lee%2C+King%E2%80%90Teh&rft.date=2014-05-01&rft.issn=1386-6346&rft.eissn=1872-034X&rft.volume=44&rft.issue=5&rft.spage=523&rft.epage=531&rft_id=info:doi/10.1111%2Fhepr.12159&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_hepr_12159 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1386-6346&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1386-6346&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1386-6346&client=summon |